Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in ...

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...